Abstract:To explore the immune status and chronic inflammation of breast cancer patients, this study aims to analyze the diagnostic value of peripheral blood lymphocyte subsets (CD3 + T, CD4 + T, CD8 + T, CD3 + CD4 − CD8 − T, CD19 + B, and NK cells) and lymphocyte-to-monocyte ratio (LMR) for breast cancer. Furthermore, it seeks to examine the correlation between these subsets and LMR with clinicopathological features.
What problem does this paper attempt to address?
### Problems the Paper Attempts to Solve
This paper aims to explore the immune status and chronic inflammation in breast cancer patients by analyzing the diagnostic value of peripheral blood lymphocyte subsets (including CD3+T, CD4+T, CD8+T, CD3+CD4−CD8−T, CD19+B, and NK cells) and the lymphocyte-to-monocyte ratio (LMR). Additionally, the study attempts to examine the correlation between these subsets and LMR with clinicopathological characteristics.
### Main Research Content
1. **Research Background**:
- Breast cancer has become the most common malignant tumor in women, with approximately 2.26 million new cases and 682,000 deaths globally each year, accounting for 15.5% of female malignant tumor mortality.
- Studies have shown that immune cells play an important role in the development of breast cancer. From the initial transformation of normal breast epithelial cells to disease progression, lymphocytes are the main effector cells of the immune response.
- The role of chronic inflammation in tumor biology is gradually being recognized. Inflammatory responses can release various inflammatory mediators, promote tumor microvascular generation, and hinder the senescence and death of tumor cells.
2. **Research Methods**:
- 100 breast cancer patients were selected as the experimental group, and 55 patients with benign breast diseases were selected as the control group.
- Statistical methods such as the Wilcoxon test, Kruskal-Wallis test, and receiver operating characteristic (ROC) curve were used to analyze the association between these serum indicators and the clinicopathological characteristics of the patients.
3. **Research Results**:
- The analysis results showed that CD3+T cells, CD4+T cells, CD8+T cells, CD4+/CD8+ ratio, NK cells, CD3+CD4−CD8−T cells, and LMR are related to the occurrence of breast cancer.
- Among them, CD3+T cells, CD4+T cells, CD4+/CD8+ ratio, CD3+CD4−CD8−T cells, and LMR were identified as independent risk factors for the development of breast cancer, with AUCs of 0.760, 0.750, 0.598, 0.697, and 0.761, respectively (P < 0.05).
- Further observations found that CD3+T cells, CD4+T cells, CD8+T cells, CD4+/CD8+ ratio, and LMR showed varying degrees of differences in lymph node metastasis, clinical staging, molecular typing, and Ki-67 levels (P < 0.05), but no statistical differences were found in histological grading and pathological types (P ≥ 0.05).
4. **Conclusion**:
- Lymphocyte subsets and LMR reflect the immune status and chronic inflammation of the body, respectively, and have certain diagnostic value for benign and malignant breast diseases. They are also related to clinicopathological characteristics such as lymph node metastasis, clinical staging, and molecular typing in breast cancer.
- Therefore, monitoring the expression of lymphocyte subsets and LMR may help in clinical auxiliary diagnosis and disease analysis.
### Significance of the Study
Currently, the clinical diagnosis of malignant breast tumors mainly relies on imaging and pathological examinations, but these methods have limitations such as high economic costs and delays. Pathological diagnosis mainly involves fine-needle aspiration cytology and core needle biopsy, which are invasive procedures that may cause psychological burden to some patients. Therefore, another diagnostic method is needed for the early detection of malignant breast tumors. This study aims to explore a serological detection indicator with diagnostic value. By combining lymphocyte subsets and LMR with clinical characteristics, it evaluates their predictive value for the occurrence, metastasis, and invasiveness of malignant breast tumors, providing new effective serological indicators for the early diagnosis of malignant breast tumors, supplementing imaging and pathological examinations.